While a few management regimens—such as nutritional support, including calories, protein, vitamin D supplementation, minerals, and dietary fibers; correction of metabolic acidosis with sodium bicarbonate; physical exercise; and modulation of gut microbiota through probiotics, prebiotics, and symbiotics—provide some benefits to address sarcopenia in CKD individuals, emerging pharmacological approaches like anabolic agents, myostatin (MSTN) inhibitors, and anti-inflammatory treatments are still under investigation [9,10,11,12]. The gene discussed is MSTN; the disease is chronic kidney disease.